VRDN - Viridian Therapeutics Inc
IEX Last Trade
14.66
-0.340 -2.319%
Share volume: 919,460
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$15.00
-0.34
-2.27%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-15 | 2022-11-14 | 2023-03-09 | 2023-05-10 | 2023-08-08 | 2023-11-13 | 2024-02-27 | 2024-05-08 | |
| Total revenue | 256.000 K | 1.195 M | 105.000 K | 98.000 K | 72.000 K | 72.000 K | 72.000 K | 72.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 256.000 K | 1.195 M | 105.000 K | 98.000 K | 72.000 K | 72.000 K | 72.000 K | 72.000 K | |
| 366.80% | -91.21% | -6.67% | -26.53% | 0.00% | 0.00% | 0.00% | |||
| Operating expenses | 29.820 M | 30.980 M | 49.171 M | 72.571 M | 59.347 M | 51.296 M | 71.550 M | 55.969 M | |
| Selling general and admin | 8.108 M | 8.861 M | 9.854 M | 21.831 M | 19.264 M | 20.911 M | 32.993 M | 15.025 M | |
| Research and development | 21.712 M | 22.119 M | 39.317 M | 50.740 M | 40.083 M | 30.385 M | 38.557 M | 40.944 M | |
| Total expenses | 29.820 M | 30.980 M | 49.171 M | 72.571 M | 59.347 M | 51.296 M | 71.550 M | 55.969 M | |
| 3.89% | 58.72% | 47.59% | -18.22% | -13.57% | 39.48% | -21.78% | |||
| Operating income | -29.564 M | -29.785 M | -49.066 M | -72.473 M | -59.275 M | -51.224 M | -71.478 M | -55.897 M | |
| Ebit | -29.564 M | -29.785 M | -49.066 M | -72.473 M | -59.275 M | -51.224 M | -71.478 M | -55.897 M | |
| Pretax income | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
| -1.99% | 58.40% | 48.85% | -19.20% | -13.44% | 40.29% | -27.40% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
| 1.99% | -58.40% | -48.85% | 19.20% | 13.44% | -40.29% | 27.40% | |||
| Net income | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
| 1.99% | -58.40% | -48.85% | 19.20% | 13.44% | -40.29% | 27.40% |